Seattle Genetics, Inc. is pleased to inform you that on April 17, 2020, the FDA approved TUKYSA tablets for oral administration. TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Please see attached full Prescribing Information HERE
Below is the product information needed to load TUKYSA.
NDC
51144-002-60 | TUKYSA (tucatinib) 150mg | Yellow, caplet-shaped tablet TUC embossed on one side, 150 on other side | 60 count tablets/bottle |
NDC
51144-001-60 | TUKYSA (tucatinib) 50mg | Yellow, round-convex tablet TUC embossed on one side, 50 on other side | 60 count tablets/bottle |
TUKYSA can be ordered through the following Specialty Distributors:
ASD Healthcare
McKesson Plasma & Biologics
Cardinal Health
McKesson Specialty Health
Oncology Supply
